Approval · Notice of Compliance 32170 · 2023
INREBIC: Notice of Compliance 32170
Issued November 23, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 32170
- Date
- November 23, 2023
- Company
- Bristol-Myers Squibb CanadaSt-Laurent, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Administrative: Change in Product Ownership
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| INREBIC | 02502445 | Marketed |
Medicinal ingredients
- FEDRATINIB 100 MG per CAP